Adjuvance Technologies, Inc

Adjuvance Technologies is a Lincoln, Nebraska-based biopharmaceutical company specializing in the design and manufacturing of innovative vaccine adjuvants. We focus on empowering global health by driving fundamental breakthroughs in immunology. Our core expertise lies in therapeutic vaccines and adjuvant immunopotentiation, offering solutions to pharmaceutical and biotechnology companies seeking to enhance vaccine efficacy. We collaborate closely with organizations like Memorial Sloan-Kettering Cancer Center to translate our research into impactful therapies.

Adjuvance Technologies develops and produces advanced adjuvant formulations, crucial for stimulating robust immune responses to vaccines. Our work supports the development of next-generation vaccines targeting a wide range of diseases, including cancer and infectious diseases. We are dedicated to accelerating vaccine development and improving patient outcomes.

Founded on a foundation of scientific excellence and entrepreneurial spirit, Adjuvance Technologies combines deep immunological knowledge with a commitment to commercialization. With a team of experienced professionals, we are uniquely positioned to deliver cutting-edge adjuvant technologies to the global market. We are a privately held company with a dedicated team of 11-50 employees.